Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase 1/2 Terminated
7 enrolled 9 charts
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
Phase 1/2 Terminated
3 enrolled
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Phase 1/2 Terminated
26 enrolled 11 charts
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Phase 1/2 Completed
45 enrolled 20 charts
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Phase 1/2 Completed
58 enrolled 12 charts
Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Phase 1/2 Completed
55 enrolled 11 charts
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
Phase 1/2 Completed
15 enrolled 13 charts
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Phase 1/2 Completed
27 enrolled 7 charts
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Phase 1/2 Completed
28 enrolled 13 charts
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Phase 1/2 Completed
10 enrolled
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
Phase 1/2 Completed
10 enrolled
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
Phase 1/2 Completed
60 enrolled